Compare ODC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | MLYS |
|---|---|---|
| Founded | 1941 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | ODC | MLYS |
|---|---|---|
| Price | $48.73 | $35.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 88.0K | ★ 1.5M |
| Earning Date | 12-08-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $478,113,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.44 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $40.66 | $8.24 |
| 52 Week High | $69.76 | $47.65 |
| Indicator | ODC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 36.08 |
| Support Level | $45.61 | $36.50 |
| Resistance Level | $54.16 | $37.75 |
| Average True Range (ATR) | 1.70 | 1.65 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 34.19 | 10.70 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.